Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1270307 | 0.85 | EGFR (0.33) | — | |
| SCHEMBL30375316 | 0.85 | EGFR (0.33) | — | |
| Trifluoroacetic Acid SCHEMBL28810979 | 0.81 | PDE3B (0.38) | HRH4HRH3L3MBTL1PAX8 | |
| Trifluoroacetic Acid SCHEMBL29713497 | 0.78 | DAO (0.48) | HRH4HRH3L3MBTL1PAX8 | |
| Trifluoroacetic Acid SCHEMBL28264177 | 0.77 | BACE1 (0.37) | HRH4HRH3L3MBTL1PAX8DPP4 | |
| Trifluoroacetic Acid SCHEMBL29627038 | 0.76 | EGLN1 (0.36) | DPP4DPP7 | |
| Trifluoroacetic Acid SCHEMBL28330487 | 0.74 | ABL1 (0.34) | HRH4HRH3L3MBTL1PAX8DPP4 | |
| Trifluoroacetic Acid SCHEMBL28780341 | 0.74 | RIPK1 (0.40) | HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL6998134 | 0.71 | ADORA3 (0.43) | L3MBTL1PAX8 | |
| Trifluoroacetic Acid SCHEMBL28162941 | 0.70 | EGFR (0.35) | HRH4HRH3L3MBTL1PAX8DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700768-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2010-04-20 | — | — | US | disclosed |
| US-7629462-B2 | Tetrasubstituted pyrimidine compounds as chemical intermediates | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090048442-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2009-02-19 | — | — | US | disclosed |
| US-20070238743-A1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2007-10-11 | — | — | US | disclosed |
| US-20070167467-A1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-7235551-B2 | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167467-A1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | MAPKAPK2, CREBBP, CNBP | HRH4 3240/4885HRH3 3785/4885L3MBTL1 1342/4885 |
| US-20070238743-A1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | MAPKAPK2, CREBBP, CNBP | HRH4 3240/4885HRH3 3785/4885L3MBTL1 1342/4885 |
| US-20090048442-A1 | Novel compounds | CREBBP, MAPKAPK2, CNBP | HRH4 3801/4885HRH3 3639/4885L3MBTL1 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.